17.82
price down icon4.23%   -0.75
 
loading
Schlusskurs vom Vortag:
$18.57
Offen:
$18.58
24-Stunden-Volumen:
273.56K
Relative Volume:
0.20
Marktkapitalisierung:
$1.94B
Einnahmen:
$525.66M
Nettoeinkommen (Verlust:
$-192.74M
KGV:
-9.5806
EPS:
-1.86
Netto-Cashflow:
$-120.97M
1W Leistung:
+7.07%
1M Leistung:
-0.64%
6M Leistung:
+27.22%
1J Leistung:
-7.85%
1-Tages-Spanne:
Value
$17.63
$18.75
1-Wochen-Bereich:
Value
$16.26
$18.75
52-Wochen-Spanne:
Value
$10.87
$24.73

Novocure Ltd Stock (NVCR) Company Profile

Name
Firmenname
Novocure Ltd
Name
Telefon
44 (0)15 3475 6700
Name
Adresse
NO. 4 THE FORUM, ST. HELIER
Name
Mitarbeiter
1,453
Name
Twitter
@novocure
Name
Nächster Verdiensttermin
2024-07-25
Name
Neueste SEC-Einreichungen
Name
NVCR's Discussions on Twitter

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-08-28 Herabstufung H.C. Wainwright Buy → Neutral
2023-08-08 Hochstufung Piper Sandler Neutral → Overweight
2023-08-04 Eingeleitet SVB Securities Outperform
2023-07-31 Hochstufung Evercore ISI Underperform → In-line
2023-06-07 Hochstufung Wedbush Underperform → Neutral
2023-05-16 Hochstufung Wells Fargo Equal Weight → Overweight
2023-03-17 Herabstufung JP Morgan Neutral → Underweight
2023-01-06 Herabstufung Wells Fargo Overweight → Equal Weight
2023-01-05 Bestätigt H.C. Wainwright Buy
2022-11-29 Hochstufung Wells Fargo Equal Weight → Overweight
2022-10-24 Herabstufung Piper Sandler Overweight → Neutral
2022-07-05 Herabstufung Evercore ISI In-line → Underperform
2022-05-16 Eingeleitet H.C. Wainwright Buy
2022-02-08 Eingeleitet Loop Capital Buy
2022-02-02 Hochstufung Oppenheimer Perform → Outperform
2022-01-20 Hochstufung Truist Hold → Buy
2022-01-03 Hochstufung Evercore ISI Underperform → In-line
2021-07-01 Herabstufung Mizuho Buy → Neutral
2021-04-14 Herabstufung Wedbush Neutral → Underperform
2021-01-25 Bestätigt Piper Sandler Overweight
2020-09-23 Eingeleitet Northland Capital Outperform
2020-09-18 Herabstufung Wells Fargo Overweight → Equal Weight
2020-09-17 Herabstufung Truist Buy → Hold
2020-06-01 Fortgesetzt Oppenheimer Perform
2020-05-01 Herabstufung Oppenheimer Outperform → Perform
2020-04-09 Herabstufung Evercore ISI In-line → Underperform
2020-03-05 Hochstufung Wells Fargo Equal Weight → Overweight
2020-01-02 Herabstufung Evercore ISI Outperform → In-line
2019-07-29 Hochstufung SunTrust Hold → Buy
2019-07-26 Herabstufung JP Morgan Overweight → Neutral
2019-07-26 Herabstufung Wedbush Outperform → Neutral
2019-03-20 Eingeleitet SunTrust Hold
2018-11-02 Herabstufung Wells Fargo Outperform → Market Perform
2018-07-16 Eingeleitet Evercore ISI Outperform
2018-04-18 Bestätigt Mizuho Buy
2018-02-23 Bestätigt Mizuho Buy
2017-05-24 Hochstufung Wells Fargo Market Perform → Outperform
2016-07-29 Bestätigt Wedbush Outperform
2016-01-19 Eingeleitet Barclays Underweight
2015-12-02 Eingeleitet Deutsche Bank Hold
Alle ansehen

Novocure Ltd Aktie (NVCR) Neueste Nachrichten

pulisher
10:53 AM

Taking on analysts’ expectations and winning: NovoCure Ltd (NVCR) - SETE News

10:53 AM
pulisher
Sep 13, 2024

Chief Financial Officer Cordova Ashley sold 688 shares of NovoCure Ltd [NVCR] - Knox Daily

Sep 13, 2024
pulisher
Sep 12, 2024

Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects - Simply Wall St

Sep 12, 2024
pulisher
Sep 11, 2024

NovoCure Ltd (NVCR) expanding its growth trajectory ahead - SETE News

Sep 11, 2024
pulisher
Sep 11, 2024

Alternating Electric Field Tumor Treatment Market Business - openPR

Sep 11, 2024
pulisher
Sep 10, 2024

Financial Health Check: Examining NovoCure Ltd (NVCR)’s Key Ratios - The Dwinnex

Sep 10, 2024
pulisher
Sep 10, 2024

NovoCure Ltd (NVCR)’s stock chart: A technical perspective - US Post News

Sep 10, 2024
pulisher
Sep 09, 2024

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy - StockTitan

Sep 09, 2024
pulisher
Sep 06, 2024

NovoCure Ltd [NASDAQ: NVCR] Sees Increase in Stock Value - Knox Daily

Sep 06, 2024
pulisher
Sep 06, 2024

Why NovoCure Stock Dived by 13% This Week - The Motley Fool

Sep 06, 2024
pulisher
Sep 06, 2024

NovoCure (NASDAQ:NVCR) Shares Down 5.5% - MarketBeat

Sep 06, 2024
pulisher
Sep 05, 2024

NovoCure (NASDAQ:NVCR) Stock Price Up 13.7% - MarketBeat

Sep 05, 2024
pulisher
Sep 05, 2024

Stock Surge: NovoCure Ltd (NVCR) Closes at 16.70, Marking a -0.30 Increase/Decrease - The Dwinnex

Sep 05, 2024
pulisher
Sep 04, 2024

NVCR November 15th Options Begin Trading - Nasdaq

Sep 04, 2024
pulisher
Sep 04, 2024

The Psychology of NovoCure Ltd Inc. (NVCR) Price Performance: Understanding Market Sentiment - The InvestChronicle

Sep 04, 2024
pulisher
Sep 03, 2024

NovoCure (NASDAQ:NVCR) Shares Gap Down to $19.44 - MarketBeat

Sep 03, 2024
pulisher
Sep 03, 2024

Novocure announces leadership transition, CEO to retire By Investing.com - Investing.com Canada

Sep 03, 2024
pulisher
Sep 03, 2024

Novocure falls as CEO Asaf Danziger to step down - XM

Sep 03, 2024
pulisher
Sep 03, 2024

There is no way NovoCure Ltd (NVCR) can keep these numbers up - SETE News

Sep 03, 2024
pulisher
Sep 03, 2024

Novocure announces leadership transition, CEO to retire - Investing.com

Sep 03, 2024
pulisher
Sep 03, 2024

Novocure announces planned CEO transition, COO to step down - TipRanks

Sep 03, 2024
pulisher
Sep 03, 2024

Novocure Announces Planned CEO Transition - Financial Times

Sep 03, 2024
pulisher
Sep 02, 2024

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Sep 02, 2024
pulisher
Aug 30, 2024

Perhaps timely catching NovoCure Ltd (NVCR) would be a good idea - SETE News

Aug 30, 2024
pulisher
Aug 30, 2024

Gaining Ground: NovoCure Ltd (NVCR) Closes Higher at 19.75, Up 0.10 - The Dwinnex

Aug 30, 2024
pulisher
Aug 29, 2024

NovoCure Ltd (NVCR) Stock: A Year of Decreases and Increases - The InvestChronicle

Aug 29, 2024
pulisher
Aug 28, 2024

NVCR’s latest rating updates from top analysts. - Knox Daily

Aug 28, 2024
pulisher
Aug 28, 2024

NovoCure (NASDAQ:NVCR) Trading Up 2.8% - MarketBeat

Aug 28, 2024
pulisher
Aug 28, 2024

What technical indicators reveal about NVCR stock - US Post News

Aug 28, 2024
pulisher
Aug 28, 2024

Novocure to Participate in 2024 Wells Fargo Healthcare Conference - Yahoo Finance

Aug 28, 2024
pulisher
Aug 28, 2024

Anaplastic Astrocytoma Market Report Details Trends, and Future Opportunities - WhaTech

Aug 28, 2024
pulisher
Aug 26, 2024

AngioDynamics (NASDAQ:ANGO) and NovoCure (NASDAQ:NVCR) Head to Head Review - Defense World

Aug 26, 2024
pulisher
Aug 25, 2024

Baillie Gifford & Co. Has $28.91 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Aug 25, 2024
pulisher
Aug 22, 2024

Insider Selling: Cordova Ashley, NovoCure Ltd [NVCR] Chief Financial Officer divested 688 shares - Knox Daily

Aug 22, 2024
pulisher
Aug 21, 2024

A better buy-in window may exist right now for NovoCure Ltd (NVCR) - SETE News

Aug 21, 2024
pulisher
Aug 20, 2024

NovoCure Ltd (NVCR) stock analysis: A simple moving average approach - US Post News

Aug 20, 2024
pulisher
Aug 19, 2024

Market Watch: NovoCure Ltd (NVCR)’s Noteworthy Drop, Closing at 17.90 - The Dwinnex

Aug 19, 2024
pulisher
Aug 17, 2024

NovoCure (MEX:NVCR) Graham Number : MXNN/A (As of Jun. 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

NovoCure (NASDAQ:NVCR) Stock Price Down 3.2% - MarketBeat

Aug 16, 2024
pulisher
Aug 16, 2024

NVCR’s 52-Week Rollercoaster: From $10.87 to $31.73 – What’s Next for Investors? - The InvestChronicle

Aug 16, 2024
pulisher
Aug 16, 2024

Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet - Yahoo Finance

Aug 16, 2024
pulisher
Aug 16, 2024

NVCR (NovoCure) 14-Day RSI : 48.34 (As of Aug. 16, 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 15, 2024

NovoCure (NASDAQ:NVCR) Trading Up 9.4% - MarketBeat

Aug 15, 2024
pulisher
Aug 15, 2024

NVCR (NovoCure) 9-Day RSI : 31.29 (As of Aug. 15, 2024) - GuruFocus.com

Aug 15, 2024
pulisher
Aug 14, 2024

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer - Yahoo Finance

Aug 14, 2024
pulisher
Aug 13, 2024

Metric Deep Dive: Understanding NovoCure Ltd (NVCR) Through its Ratios - The Dwinnex

Aug 13, 2024
pulisher
Aug 13, 2024

NovoCure Ltd (NVCR)’s stock performance: a year in review - US Post News

Aug 13, 2024
pulisher
Aug 10, 2024

Is Spruce Biosciences Inc (NASDAQ: SPRB) A Good Investment Now? - Stocks Register

Aug 10, 2024
pulisher
Aug 10, 2024

Metrics That Matter About Ionis Pharmaceuticals Inc (NASDAQ: IONS) - Stocks Register

Aug 10, 2024
pulisher
Aug 10, 2024

Things To Consider Before Buying CBRE Group Inc (NYSE: CBRE) - Stocks Register

Aug 10, 2024
pulisher
Aug 10, 2024

The Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Stock Price: Is It Overvalued? - Stocks Register

Aug 10, 2024

Finanzdaten der Novocure Ltd-Aktie (NVCR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Novocure Ltd-Aktie (NVCR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Jun 05 '24
Option Exercise
22.82
124,373
2,838,192
124,373
VERNON W ANTHONY
Director
Jun 04 '24
Sale
23.89
964
23,033
164,833
Scannell Timothy J
Director
Jun 04 '24
Sale
23.89
964
23,027
2,964
LEUNG GABRIEL
Director
Jun 04 '24
Sale
23.89
964
23,025
78,175
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Mar 01 '24
Sale
16.03
2,107
33,769
252,452
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Mar 04 '24
Sale
16.01
1,217
19,484
251,235
Leonard Frank X
EVP, Pres., Novocure Oncology
Mar 01 '24
Sale
16.03
1,679
26,909
160,938
Leonard Frank X
EVP, Pres., Novocure Oncology
Mar 04 '24
Sale
16.01
840
13,448
160,098
Leonard Frank X
EVP, Pres., Novocure Oncology
Feb 28 '24
Sale
16.14
2,078
33,545
162,617
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Feb 28 '24
Sale
16.14
2,303
37,177
254,559
medical_devices ZBH
$107.41
price up icon 1.05%
medical_devices STE
$243.22
price down icon 0.60%
$70.65
price up icon 1.73%
medical_devices PHG
$30.94
price up icon 0.63%
$86.76
price down icon 0.16%
medical_devices EW
$68.98
price up icon 0.69%
Kapitalisierung:     |  Volumen (24h):